Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Vertex Pharmaceutic (VRTX)

Vertex Pharmaceutic (VRTX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 58,651,568
  • Shares Outstanding, K 260,038
  • Annual Sales, $ 4,163 M
  • Annual Income, $ 1,177 M
  • 60-Month Beta 0.78
  • Price/Sales 9.92
  • Price/Cash Flow 47.45
  • Price/Book 7.23
Trade VRTX with:

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 20 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/20
See More
  • Average Estimate 2.29
  • Number of Estimates 8
  • High Estimate 2.56
  • Low Estimate 2.12
  • Prior Year 1.44
  • Growth Rate Est. (year over year) +59.03%

Price Performance

See More
Period Period Low Period High Performance
1-Month
222.31 +1.46%
on 01/06/21
239.71 -5.91%
on 12/18/20
-3.26 (-1.42%)
since 12/15/20
3-Month
202.57 +11.35%
on 11/02/20
239.71 -5.91%
on 12/18/20
+10.27 (+4.77%)
since 10/15/20
52-Week
197.47 +14.22%
on 03/18/20
306.08 -26.31%
on 07/07/20
-8.60 (-3.67%)
since 01/15/20

Most Recent Stories

More News
Vertex Pharmaceuticals (VRTX) Stock Moves -0.25%: What You Should Know

In the latest trading session, Vertex Pharmaceuticals (VRTX) closed at $225.55, marking a -0.25% move from the previous day.

VRTX : 225.55 (-0.25%)
Huntington's Disease Therapeutics Market Global Trends, Market Share, Industry Size, Growth, Opportunities and Market Forecast 2020 to 2027

The research report titled Huntington's Disease Therapeutics offers comprehensive information on key driving factors, pricing analysis, market growth trends, brand positioning, competitive landscape, product...

APHB : 0.32 (-20.33%)
CORX : 1.0200 (+385.71%)
GSK : 38.47 (+0.81%)
PRAN : 2.06 (unch)
RPTP : 9.00 (unch)
VRX.TO : 30.80 (-3.33%)
VRTX : 225.55 (-0.25%)
3 Biotech Stocks Poised to Outperform Amid Coronavirus Pandemic

3 Biotech Stocks Poised to Outperform Amid Coronavirus Pandemic

VRTX : 225.55 (-0.25%)
REGN : 517.93 (unch)
NVAX : 127.43 (-1.96%)
HALO : 47.43 (+0.81%)
GILD : 63.33 (+1.49%)
BPMC : 100.99 (-1.48%)
BIIB : 275.84 (-1.59%)
Vertex Pharm Set to Possibly Pullback After Yesterday's Rally of 1.65%

Vertex Pharm (NASDAQ:VRTX) traded in a range yesterday that spanned from a low of $234.50 to a high of $237.87. Yesterday, the shares gained 1.6%, which took the trading range above the 3-day high of...

VRTX : 225.55 (-0.25%)
The Zacks Analyst Blog Highlights: Intellia Therapeutics, Editas Medicine, Fate Therapeutic, CRISPR Therapeutics and Vertex Pharmaceuticals

The Zacks Analyst Blog Highlights: Intellia Therapeutics, Editas Medicine, Fate Therapeutic, CRISPR Therapeutics and Vertex Pharmaceuticals

VRTX : 225.55 (-0.25%)
FATE : 113.59 (-3.25%)
EDIT : 76.14 (+0.29%)
NTLA : 81.89 (-1.69%)
CRSP : 199.88 (-4.84%)
Vertex Pharmaceuticals (VRTX) Outpaces Stock Market Gains: What You Should Know

Vertex Pharmaceuticals (VRTX) closed at $237 in the latest trading session, marking a +1.76% move from the prior day.

VRTX : 225.55 (-0.25%)
CRISPR Gene Editing Stocks Up After Intellia's Pipeline Update

Shares of Intellia were up as the update on its gene-editing drugs excited investors. The news also pushed up stocks of companies making gene-editing drugs, FATE, CRSP, EDIT, using CRISPR technology.

VRTX : 225.55 (-0.25%)
FATE : 113.59 (-3.25%)
EDIT : 76.14 (+0.29%)
NTLA : 81.89 (-1.69%)
CRSP : 199.88 (-4.84%)
Huntington's Disease Treatment Market Various Segments And Sub-Segments, Estimated Future Revenue, Supply Chain Analysis, Porters Five Force And Country Level Analysis By 2023

APHB : 0.32 (-20.33%)
CORX : 1.0200 (+385.71%)
GSK : 38.47 (+0.81%)
PRAN : 2.06 (unch)
RPTP : 9.00 (unch)
TEVA : 11.96 (+4.00%)
VRX.TO : 30.80 (-3.33%)
VRTX : 225.55 (-0.25%)
3 Biotech Technological Developments to Watch Out For in 2021

Here we discuss three booming technological developments in the biotech sector, which can capture investor attention in 2021

RHHBY : 44.5600 (+1.39%)
PFE : 36.70 (-0.14%)
VRTX : 225.55 (-0.25%)
ABBV : 110.52 (-0.99%)
EDIT : 76.14 (+0.29%)
NTLA : 81.89 (-1.69%)
CRSP : 199.88 (-4.84%)
Vertex to Present at the J.P. Morgan Healthcare Conference on January 11

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that management will present at the J.P. Morgan Healthcare Conference on Monday, January 11, 2021 at 9:10 a.m. ET (6:10 a.m. PT).

JPM : 138.64 (-1.79%)
VRTX : 225.55 (-0.25%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 80% Sell with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Vertex Pharmaceuticals Incorporated is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious and life-threatening diseases. In addition to clinical development programs in CF, Vertex has more than a dozen ongoing research programs...

See More

Key Turning Points

3rd Resistance Point 230.51
2nd Resistance Point 229.06
1st Resistance Point 227.30
Last Price 225.55
1st Support Level 224.09
2nd Support Level 222.64
3rd Support Level 220.88

See More

52-Week High 306.08
Fibonacci 61.8% 264.59
Fibonacci 50% 251.77
Fibonacci 38.2% 238.96
Last Price 225.55
52-Week Low 197.47

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar